5 Crescent Drive
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer.
Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.
The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.
Based on 2000 Preliminary Annual Results, GSK had sales of £18.1 billion ($27.5 billion) and profit before tax of £5 billion ($8.1 billion). Pharmaceutical sales accounted for £15.4 billion ($23.5 billion), 85 per cent of the total.
GSK had four products with sales of over $1 billion and a total of 16 products with sales in excess of $500 million.
GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Almost 40,000 employees work at 108 manufacturing sites in 41 countries and over 16,000 are in R&D.
2965 articles with GlaxoSmithKline
The two companies are eying the second half of this year to begin clinical trials on their combined project and, if the vaccine meets expectations, the companies said it could be available for use in the second half of 2021.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
Voltaren Arthritis Pain and the Arthritis Foundation Announce Multi-Year Partnership to Help People Living with Osteoarthritis
GlaxoSmithKline (LSE/NYSE: GSK) today announced a multi-year partnership with the Arthritis Foundation to support scientific research, advocacy as well as virtual resources and community connections for the more than 30 million people in America living with osteoarthritis (OA)
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks Promising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical trials within the next three to five months GSK to make equity investment of $250 million in Vir LONDON and SAN FRANCISCO, April 06, 2020 (GLOBE NEWSWIRE) -- LSE announcement -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.
Following months of concerns regarding the potential contamination of ranitidine-based products with known carcinogens, the U.S. Food and Drug Administration is asking manufacturers to immediately withdraw all prescription and over-the-counter drugs from the market.
As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection ...
Agenus Inc., an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, announced the triggering of a $15.1M milestone payment from HealthCare Royalty Partners based on net sales of GlaxoSmithKline's Shingrix vaccine exceeding $2.0B in 2019.
Unique public-private collaboration provides continued funding for HIV Cure Center and Qura Therapeutics, the joint venture that brings academic and pharmaceutical research scientists together
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
The drugs in question bring in about $200 million annually.
FDA approves GSK's Advil Dual Action with Acetaminophen for over-the-counter use in the United States
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Advil Dual Action with Acetaminophen as an over-the-counter (OTC) product for pain relief.
GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma
GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the acceptance of a regulatory submission seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) for the treatment of asthma in adults by the European Medicines Agency (EMA).
European Medicines Agency accepts submission of GSK's Marketing Authorisation Application for Zejula (niraparib) in first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
Submission based on data from the Phase III PRIMA clinical study that demonstrated clinically meaningful outcomes of niraparib maintenance treatment in the first-line setting regardless of biomarker status
The FDA is reviewing the sNDA under the Real-Time Oncology Review (RTOR) pilot program, which could speed up the process for potential approval.
U.S. FDA accepts GSK's sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
Submission based on data from the Phase III PRIMA clinical study that demonstrated clinically-meaningful outcomes of niraparib maintenance treatment in the first-line setting regardless of biomarker status - The application is being reviewed under the FDA's Real-Time Oncology Review pilot program LONDON , Feb. 24, 2020 /PRNewswire/ -- GlaxoSmithKline plc today
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System
Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.